A Single Institution Experience of Incorporation of Cisplatin into Adjuvant Chemotherapy for Patients With Triple-Negative Breast Cancer of Unknown Mutation Status

A Single Institution Experience of Incorporation of Cisplatin into Adjuvant Chemotherapy for Patients With Triple-Negative Breast Cancer of Unknown Mutation Status

The clinical benefit of adding platinum to adjuvant chemotherapy for patients with triple-negative breast cancer (TNBC) has not been well investigated, although it was associated an improved response rate in neoadjuvant setting. We retrospectively analyzed the time to tumor progression (TTP) and ove...

Full description

Bibliographic Details
Main Authors: Ying-Wen Su, Chia-Yen Hung, Hung-Bun Lam, Yuan-Ching Chang, Po-Sheng Yang
Format: Article
Language:English
Published: SAGE Publishing 2018-08-01
Series:Clinical Medicine Insights: Oncology
Online Access:https://doi.org/10.1177/1179554918794672

Internet

https://doi.org/10.1177/1179554918794672

Similar Items